Cargando…

Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences

Diabetic retinopathy is one of the worst complications of diabetes and it is treated by invasive method. We prepared a surface modified poly (D, L-lactide-co-glycolide) i.e. PLGA nanoparticles for delivery of pioglitazone-a peroxisome proliferator-activated receptor-gamma agonist to posterior segmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laddha, Umesh D., Kshirsagar, Sanjay J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432955/ https://www.ncbi.nlm.nih.gov/pubmed/32832706 http://dx.doi.org/10.1016/j.heliyon.2020.e04589

Ejemplares similares

Potential therapeutic effects of naringin loaded PLGA nanoparticles for the management of Alzheimer's disease: In vitro, ex vivo and in vivo investigation
por: Dashputre, Neelam L., et al.
Publicado: (2023)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer’s disease: in vitro and in vivo studies
por: Silva-Abreu, Marcelle, et al.
Publicado: (2018)

Formulation and Evaluation of Pravastatin Sodium-Loaded PLGA Nanoparticles: In vitro–in vivo Studies Assessment
por: Elsayed, Seham I, et al.
Publicado: (2023)

PPARγ Agonist-Loaded PLGA-PEG Nanocarriers as a Potential Treatment for Alzheimer’s Disease: In vitro and in vivo Studies [Corrigendum]
Publicado: (2023)

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
por: Treacy, Maxwell P, et al.
Publicado: (2012)

Neuroprotective effect of insulin-loaded chitosan nanoparticles/PLGA-PEG-PLGA hydrogel on diabetic retinopathy in rats
por: Rong, Xianfang, et al.
Publicado: (2018)

Investigating the Effect of Surface Hydrophilicity on the Destiny of PLGA-Poloxamer Nanoparticles in an In Vivo Animal Model
por: Silvestri, Teresa, et al.
Publicado: (2023)

Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT
por: Hill, Marcus, et al.
Publicado: (2019)

Formulation of PLGA nanoparticles containing short cationic peptide nucleic acids
por: Malik, Shipra, et al.
Publicado: (2020)

PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters
por: Hernández-Giottonini, Karol Yesenia, et al.
Publicado: (2020)

Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles
por: Fodor-Kardos, Andrea, et al.
Publicado: (2020)

Trastuzumab- and Fab′ fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo
por: Duan, Dongyu, et al.
Publicado: (2018)

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
por: Chen, Ying, et al.
Publicado: (2013)

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
por: Carta, Anna R., et al.
Publicado: (2011)

Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver
por: Rogue, Alexandra, et al.
Publicado: (2010)

Formulation and Characterization of Antigen-loaded PLGA Nanoparticles for Efficient Cross-priming of the Antigen
por: Lee, Young-Ran, et al.
Publicado: (2011)

PLGA Biodegradable Nanoparticles Containing Perphenazine or Chlorpromazine Hydrochloride: Effect of Formulation and Release
por: Halayqa, Mohammed, et al.
Publicado: (2014)

Formulation and In vitro Interaction of Rhodamine-B Loaded PLGA Nanoparticles with Cardiac Myocytes
por: Jonderian, Antranik, et al.
Publicado: (2016)

Formulation, Characterization and Cytotoxicity Effects of Novel Thymoquinone-PLGA-PF68 Nanoparticles
por: Noor, Nurul Shahfiza, et al.
Publicado: (2021)

Lectin-Modified Magnetic Nano-PLGA for Photodynamic Therapy In Vivo
por: Kovalenko, Vera L., et al.
Publicado: (2022)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer
por: Sims, Lee B., et al.
Publicado: (2016)

Chitosan-Modified PLGA Nanoparticles for Control-Released Drug Delivery
por: Lu, Boting, et al.
Publicado: (2019)

Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist Pioglitazone
por: Lamounier, Rodrigo N, et al.
Publicado: (2013)

Role of Phytoconstituents as PPAR Agonists: Implications for Neurodegenerative Disorders
por: , Sanjay, et al.
Publicado: (2021)

The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
por: Stunes, Astrid K, et al.
Publicado: (2011)

Formulation, Characterization And Evaluation Of Curcumin- Loaded PLGA- TPGS Nanoparticles For Liver Cancer Treatment
por: Chen, Xiao-ping, et al.
Publicado: (2019)

Formulation of tunable size PLGA-PEG nanoparticles for drug delivery using microfluidic technology
por: Mares, Adrianna Glinkowska, et al.
Publicado: (2021)

Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation
por: Hu, Sanyuan, et al.
Publicado: (2010)

Surface Characteristics Affect the Properties of PLGA Nanoparticles as Photothermal Agents
por: Kovalenko, Vera L., et al.
Publicado: (2023)

Preparation of PLGA Nanoparticles by Milling Spongelike PLGA Microspheres
por: Lee, Jimin, et al.
Publicado: (2022)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Formulation and development of plasma volume expander using natural and modified starch from Solanum tuberosum
por: Thombre, Nilima A., et al.
Publicado: (2016)

Investigation and optimization of formulation parameters on preparation of targeted anti-CD205 tailored PLGA nanoparticles
por: Jahan, Sheikh Tasnim, et al.
Publicado: (2015)

Formulation, Cellular Uptake and Cytotoxicity of Thymoquinone-Loaded PLGA Nanoparticles in Malignant Melanoma Cancer Cells
por: Ibrahim, Wisam Nabeel, et al.
Publicado: (2020)

Dry Tablet Formulation of PLGA Nanoparticles with a Preocular Applicator for Topical Drug Delivery to the Eye
por: Ryu, Woo Mi, et al.
Publicado: (2019)

5-Fluorouracil-Loaded PLGA Nanoparticles: Formulation, Physicochemical Characterisation, and In VitroAnti-Cancer Activity
por: Gahtani, Reem M., et al.
Publicado: (2023)

Comparison of bulk and microfluidics methods for the formulation of poly-lactic-co-glycolic acid (PLGA) nanoparticles modified with cell-penetrating peptides of different architectures
por: Streck, Sarah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1dof2urgmggemtlj6emfriins8